Drugs / Meclofenamate
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | MECLOMEN | — | 1988-08-30 – 1990-07-23 | fda.gov ↗ |
| Approved | US (FDA) | MECLOMEN | — | 1980-06-25 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02429570 | Apr 2015 → Apr 2027 expected | metastatic malignant neoplasm in the brain | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meclofenamate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02429570 ↗ |
| Known as | meclofenamic acid | “This narrative review resumes the effects of niflumic acid (NFA), flufenamic acid (FFA), mefenamic acid (MFA), meclofenamic acid (MCFA), and tolfenamic acid (TFA) on different...” PMID 40568930 ↗ Aug 2025 |
| Modality | Small molecule | “fenamates might be considered promising lead compounds for the development of new drug candidates” PMID 40568930 ↗ Aug 2025 |
| Route | Oral | “All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.” NCT02429570 ↗ |